NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Science"
DOI: 10.1111/cas.15243
Abstract: The challenge to improve the clinical efficacy and enlarge the population that benefits from immune checkpoint inhibitors (ICIs) for non‐small‐cell lung cancer (NSCLC) is significant. Based on whole‐exosome sequencing analysis of biopsies from NSCLC patients… read more here.
Keywords: programmed cell; death protein; cell death; ligand therapy ... See more keywords